Impact of Fever Prevention in Brain Injured Patients

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 686 participants.

Also called NCT02996266

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 686 participants (enrolled count) (from the registry)
Sponsor
  • C. R. Bard Registry lists this organization as the lead sponsor
  • Yale University Registry lists this organization as a collaborator
Registry
  • NCT NCT02996266
Other papers using this trial's data
  • Fever Prevention in Patients With Acute Vascular Brain Injury: The INTREPID Randomized Clinical Trial JAMA, 2024-11-12 DOI, PubMed 39320879, PMC11425189 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Germany, South Korea, Switzerland (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02996266. Randomized; single masking; primary purpose treatment. Start 2017-01 (actual); primary completion 2022-05-12 (actual). Results posted on 2023-09-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Impact of Fever Prevention in Brain Injured Patients
Acronym
INTREPID
Condition
Fever
Condition
Intracerebral Hemorrhage
Condition
Subarachnoid Hemorrhage
Intervention (Device)
Targeted Temperature Management
Intervention (Other)
Standard Care
Lead sponsor
C. R. Bard (class: industry)
Collaborator
Yale University (class: other)
Collaborator
Boston University (class: other)

Record details

Record id
cardio:ct-nct02996266
Content hash
56ecb49bb87b3e96695452fa4b6334ad46ae16835e3e758763ec1f192127aabf